Fried v. AdaptHealth LLC

CourtDistrict Court, D. Delaware
DecidedApril 17, 2025
Docket1:24-cv-00305
StatusUnknown

This text of Fried v. AdaptHealth LLC (Fried v. AdaptHealth LLC) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fried v. AdaptHealth LLC, (D. Del. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MICHAEL FRIED, Plaintiff, v. 5 C.A. No. 24-305-GBW ADAPTHEALTH, LLC, Defendant. MEMORANDUM ORDER At Wilmington this 17th day of April 2025: Plaintiff Michael Fried (“Plaintiff’ or “Fried”) brings this action against Defendant AdaptHealth, LLC (“Defendant” or ““AdaptHealth”). Presently before the Court is Defendant’s Motion to Dismiss (D.I. 14) (“the Motion”). The Motion is fully briefed. (D.I. 24; D.I.25). For the reasons explained below, the Court DENIES Defendant’s Motion. I. BACKGROUND! AdaptHealth is a Delaware limited liability company that provides home medical supplies and equipment. (DJ. 1 § 2). In 2021, AdaptHealth hired Fried to serve as the President of Community Surgical Supply of Toms River, LLC (“CSS”).? (id. $7). On December 30, 2021, AdaptHealth and Fried entered into an employment agreement (“the Employment Agreement.”). (id. J 6; see also D.I. 1, Ex. A). The Employment Agreement provides for three potential forms of compensation to Fried: (1) a base salary of $350,000 per year; (2) a bonus based on performance; and (3) incentive compensation. (D.I. 1, Ex. A, §3(a)-(e)). Specifically, the incentive

} At this stage, the Court accepts the factual assertions in Plaintiff's Complaint as true. See Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). 2 Toms River, LLC is an entity owned by AdaptHealth. (D.I. 1 4 7).

compensation section of the Employment Agreement (“the Incentive Compensation Section”) provides: (e) Incentive Compensation. The Employee shall receive “Incentive Compensation” based on CSS exceeding certain annual net revenue thresholds in calendar year 2022. Specifically, the Employee shall be eligible to receive (i) 10% of net revenue from operations in New York and New Jersey that results in infusion pharmacy gross margin in excess of $6,500,000 for CSS in calendar year 2022, and (ii) 10% of net revenue in excess of $7,800,000 from the Ohio Veteran’s Administration contract number 36C25021D0015 for CSS in calendar year 2022. For purposes herein, gross margin means net revenue less cost of goods sold. [...] (Id. §3(e)).° In October 2022, Fried and AdaptHealth decided to terminate the Employment Agreement. To memorialize the termination, on October 14, 2022, the parties executed a severance agreement and general release (“the Severance Agreement”). (D.I. 1 4 9; see also D.I. 1, Ex. B). The Severance Agreement provides that Fried would receive: (1) severance pay to total his gross anticipated salary of $350,000; (2) a bonus payment of $175,000; and (3) the incentive compensation provided for in the Employment Agreement. (D.I. 1, Ex. B §7). The incentive compensation section of the Severance Agreement states that “[AdaptHealth] acknowledges that CSS ... expects to achieve the annual net revenue threshold set forth in Section 3(e)(i) of the Employment Agreement for calendar year 2022 . . . [and] will pay Employee the Incentive

3 The Court will refer to the first part of the Incentive Compensations Section as “Section 3(e)(1)” and the latter part as “Section 3(e)(ii).”

Compensation (as defined in and determined pursuant to the Employment Agreement).” □□□□ §7(c)). result, pursuant to Section 3(e)(i) of the Employment Agreement, AdaptHealth paid Fried $249,416.00 in incentive compensation. (D.IJ. 1 7 11). AdaptHealth calculated Fried’s incentive compensation by taking 10% of the approximate “$2.5 million of net revenue that resulted in gross margin in excess of $6.5 million.” (D.I. 14 at 2). Fried, however, alleges he should have received “$1,663,234.00” in incentive compensation based on CSS’s financial performance, as reflected in AdaptHealth’s audited financials. (/d.). Fried calculated this figure by taking 10% of ail net revenue because CSS’s gross margin exceeded $6.5 million. Consequently, Fried demands an additional “$1,413,908.00” in incentive compensation from AdaptHealth. (/d.). II. PROCEDURAL POSTURE On March 7, 2024, Plaintiff filed a Complaint (D.I. 1) (“the Complaint”). In the Complaint, Plaintiff asserts two causes of action: (1) breach of contract, and (2) violation of the Delaware Wage Payment and Collection Act. (D.I. 1). Plaintiff requests an award of damages in an amount no less than $1,413,908.00, attorneys’ fees, costs, and expenses, and all other relief the Court deems just and proper. (/d.). On May 6, 2024, Defendant filed a Motion to Dismiss for Failure to State a Claim (D.J. 14) (“the Motion”). On June 5, 2024, Plaintiff filed an Answering Brief in Opposition to the Motion (D.I. 24). On June 20, 2024, Defendant filed a Reply Brief in support of its Motion (D.I. 25). il. LEGAL STANDARD A. — Rule 12(b)(6) Under Federal Rule of Civil Procedure 12(b)(6) (‘Rule 12(b)(6)”), a complaint must be dismissed if it “[fails] to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). The purpose of a Rule 12(b)(6) motion is to test the legal sufficiency of acomplaint. E.f DuPont

de Nemours & Co. v. Great Lakes Chem. Corp., 383 F. Supp. 2d 642, 644-45 (D. Del. 2005). “To survive a Rule 12(b)(6) motion, a complaint must set forth enough factual allegations to ‘state a claim to relief that is plausible on its face."” Klotz v. Celentano Stadtmauer & Walentowicz LLP, 991 F.3d 458, 462 (3d Cir. 2021) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)). A claim for relief is facially plausible “when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). When reviewing a motion to dismiss under Rule 12(b)(6), the Court must “consider only the complaint, exhibits attached to the complaint, matters of public record, as well as undisputedly authentic documents if the complainant’s claims are based upon these documents.” Mayer v. Belichick, 605 F.3d 223, 230 (3d Cir. 2010). Additionally, the Court must construe all allegations and facts in the light most favorable to the non-movant plaintiff and resolve all reasonable inferences in the plaintiffs favor. See Evancho v. Fisher, 423 F.3d 347, 350 (3d Cir. 2005); see also Rocks v. City of Philadelphia, 868 F.2d 644, 645 (3d Cir. 1989). The Court, however, need not accept “bald assertions,” “unsupported conclusions,” or “unwarranted inferences.” Morse v. Lower Merion Sch. Dist., 132 F.3d 902, 906, at n.8 (3d Cir. 1997) (internal quotation marks omitted). Instead, “[t]he complaint must state enough facts to raise a reasonable expectation that discovery will reveal evidence of [each] necessary element” of a plaintiff's claim. Wilkerson v. New Media Tech. Charter Sch., Inc., 522 F.3d 315, 321 (3d Cir. 2008) (internal quotation marks and citations omitted). B.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Mayer v. Belichick
605 F.3d 223 (Third Circuit, 2010)
Rocks v. City of Philadelphia
868 F.2d 644 (Third Circuit, 1989)
Evancho v. Fisher
423 F.3d 347 (Third Circuit, 2005)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Kaiser Aluminum Corp. v. Matheson
681 A.2d 392 (Supreme Court of Delaware, 1996)
Allied Capital Corp. v. GC-Sun Holdings, L.P.
910 A.2d 1020 (Court of Chancery of Delaware, 2006)
VLIW TECHNOLOGY, LLC v. Hewlett-Packard Co.
840 A.2d 606 (Supreme Court of Delaware, 2003)
E.I. DuPont De Nemours & Co. v. Great Lakes Chemical Corp.
383 F. Supp. 2d 642 (D. Delaware, 2005)
AES Puerto Rico, L.P. v. ALSTOM Power, Inc.
429 F. Supp. 2d 713 (D. Delaware, 2006)
Terry Klotz v. Celentano Stadtmauer and Wale
991 F.3d 458 (Third Circuit, 2021)
Astellas Pharma, Inc. v. Sandoz Inc.
117 F.4th 1371 (Federal Circuit, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
Fried v. AdaptHealth LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fried-v-adapthealth-llc-ded-2025.